DHI
48
4
M
37
12
MAS
58
2
MRK
25
-2
VZ
50
3
WBA
48
4
ROST
63
12
SE
61
-4
FLR
58
3
MLM
57
6
CRM
67
2
SIG
52
3
NSC
60
3
WDC
47
4
XYL
49
4
BF.B
33
2
SLB
55
2
XRAY
28
2
RHI
59
2
NEE
50
-5
DHI
48
4
M
37
12
MAS
58
2
MRK
25
-2
VZ
50
3
WBA
48
4
ROST
63
12
SE
61
-4
FLR
58
3
MLM
57
6
CRM
67
2
SIG
52
3
NSC
60
3
WDC
47
4
XYL
49
4
BF.B
33
2
SLB
55
2
XRAY
28
2
RHI
59
2
NEE
50
-5
Financhill
Back

EyePoint Pharmaceuticals 10K Form

Buy
61

EYPT
EyePoint Pharmaceuticals

Last Price:
8.94
Seasonality Move:
28.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive EYPT News And Ratings

See the #1 stock for the next 7 days that we like better than EYPT

EYPT Financial Statistics

Sales & Book Value

Annual Sales: $46.02M
Cash Flow: $-40.6M
Price / Cash Flow: 0
Annual Sales: $4.09
Price / Book: 2.79

Profitability

EPS (TTM): -1.99000
Net Income (TTM): $-103.57M
Gross Margin: $41.39M
Return on Equity: -50.67%
Return on Assets: -35.24%

EyePoint Pharmaceuticals Earnings Forecast

Key EyePoint Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 16 years for EYPT is 89.93%.
  • The Selling, General & Administrative Expenses for EYPT have been equal to 112.55% of Gross Profit Margin.
  • The Research & Development expenses have been 140.51% of Revenue.
  • The Interest Expense is -1.76% of Operating Income.
  • The Net Earning history of EYPT is -153.84% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 10 years.

EyePoint Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: EYPT
CUSIP: 30233G
Website: eyepointpharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.5
Quick Ratio: 5.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

EYPT Technical Analysis vs Fundamental Analysis

Buy
61
EyePoint Pharmaceuticals (EYPT) is a Buy

Is EyePoint Pharmaceuticals a Buy or a Sell?